Evidence map›Paper›PMID 38469626›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2024

Functional roles of CD26/DPP4 in lipopolysaccharide-induced lung injury.

Shun Sato, Takeshi Kawasaki, Ryo Hatano, Yu Koyanagi, Yukiko Takahashi, Kei Ohnuma, Chikao Morimoto, Steven M Dudek, Koichiro Tatsumi, Takuji Suzuki

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Orexin Receptor Antagonism Improves Sleep Quality and Mitigates Lipopolysaccharide-Induced Inflammatory Responses in a Mouse Model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Shun SatoDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takeshi KawasakiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID 0000-0002-1468-172X
Ryo HatanoDepartment of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Yu KoyanagiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yukiko TakahashiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kei OhnumaDepartment of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Chikao MorimotoDepartment of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Steven M DudekDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States.ORCID 0000-0001-5624-0714
Koichiro TatsumiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takuji SuzukiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JPJuntendo University · JPUniversity of Illinois Chicago · US

Funding

AMED-CREST 23gm1810009h0001GSK Japan Research Grant 2019Japan Agency for Medical Research and Development (AMED) 223fa627003h0001MEXT | Japan Society for the Promotion of Science (JSPS) 19K17663MEXT | Japan Society for the Promotion of Science (JSPS) 22H03076MEXT | Japan Society for the Promotion of Science (JSPS) 22K16163MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JP21gm1210003The Ministry of Health, Labor and Welfare, Japan 20FC1027The Ministry of Health, Labor and Welfare, Japan 21FC1027Therapeutics Research Initiative Grant from Chiba University School of Medicine 2019-G6
6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS) is characterized by dysregulated inflammation and increased permeability of lung microvascular cells. CD26/dipeptidyl peptidase-4 (DPP4) is a type II membrane protein that is expressed in several cell types and mediates multiple pleiotropic effects. We previously reported that DPP4 inhibition by sitagliptin attenuates lipopolysaccharide (LPS)-induced lung injury in mice. The current study characterized the functional role of CD26/DPP4 expression in LPS-induced lung injury in mice, isolated alveolar macrophages, and cultured lung endothelial cells. In LPS-induced lung injury, inflammatory responses [bronchoalveolar lavage fluid (BALF) neutrophil numbers and several proinflammatory cytokine levels] were attenuated in

Indexed as

Dipeptidyl Peptidase 4LipopolysaccharidesMacrophages, AlveolarAcute Lung InjuryAnimalsBronchoalveolar Lavage FluidCapillary PermeabilityCells, CulturedEndothelial CellsIntercellular Adhesion Molecule-1Interleukin-6LungLung InjuryMaleMiceMice, Inbred C57BLDipeptidyl Peptidase 4Dpp4 protein, mouseIntercellular Adhesion Molecule-1Interleukin-6LipopolysaccharidesTumor Necrosis Factor-alphaacute respiratory distress syndromeCD26DPP4LPSlung injury

Identifiers

PMID38469626
PMCPMC11905807
OpenAlexW4392710891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.